News

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC)…
Read More...

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), announced that it has entered into a Master Development and Commercialization Agreement with…
Read More...

Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s…
Read More...

Particle Sciences, a Lubrizol LifeSciences company and pharmaceutical contract development and manufacturing organization (CDMO), has broadened its Drug Enforcement Administration (DEA)…
Read More...

Merz, a global leader in neurotoxin therapy, announced the European approval of Xeomin (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to…
Read More...

Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.  This agreement allows for…
Read More...

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The…
Read More...

Allergan plc and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for…
Read More...

Vibalogics GmbH, a contract development and manufacturing organization (CDMO) focused on complex live biological products, is being acquired by Ampersand Capital Partners, a private…
Read More...

Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of…
Read More...

Modulus Discovery, an early stage global biopharmaceutical company, announced the signing of research data transfer agreement on a specific drug target with Astellas Pharma. Under…
Read More...

Epizyme, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of…
Read More...

Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, announced that the U.S. Food and Drug Administration (FDA) has…
Read More...

AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including metastatic breast cancer (MBC), announced that the…
Read More...

Prestige BioPharma announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar…
Read More...

Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from…
Read More...

Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania (Penn) announced a major expansion to their collaboration with rights to pursue collaborative…
Read More...

Almac Sciences, a member of the Almac Group, announced the appointment of Dr Sheryl Foster to the position of Vice President of Quality, reporting to Managing Director & President,…
Read More...

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S. Ranolazine…
Read More...

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing…
Read More...